The Unmet Need Driving Cervical Cancer Pipeline Investment
Cervical cancer is the fourth most frequently diagnosed cancer in women worldwide, with approximately 570,000 new cases annually. The five-year relative survival rate for stage IV disease sits at just 15%, creating a critical unmet medical need — particularly in recurrent, metastatic, or platinum-refractory settings — that is now attracting concentrated patent activity from global pharmaceutical companies.
The retrieved patent dataset captures active innovation across three converging therapeutic pillars: anti-tissue factor (TF) antibody-drug conjugates (ADCs) led by tisotumab vedotin, PD-1/PD-L1 immune checkpoint inhibitors, and emerging combination strategies involving novel co-targets such as TIGIT, HER2, and ICOS. According to data tracked by WHO, cervical cancer disproportionately burdens low- and middle-income countries, making therapeutic advances in advanced-stage disease a global health priority.
This analysis is derived from a targeted set of patent and literature records. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
Five distinct molecular targets emerge consistently across the retrieved filings: Tissue Factor (TF/F3), PD-1/PD-L1, HPV oncoproteins E6/E7, HER2, and the TIGIT–PVR axis. Each represents a different mechanistic rationale for therapeutic intervention, and several are now being combined in multi-target strategies. As tracked by NIH research programmes, the intersection of HPV biology and immune checkpoint regulation is an area of particular translational interest.
Cervical cancer is the fourth most frequently diagnosed cancer in women worldwide, with approximately 570,000 new cases annually and a five-year relative survival rate of only 15% for stage IV disease, according to patent filings analysed in the PatSnap Eureka dataset.
Tisotumab Vedotin: The Most Patent-Dense ADC in Cervical Cancer
Tisotumab vedotin (TV) is the most cervical cancer-specific antibody-drug conjugate in the retrieved dataset. TV targets Tissue Factor (TF), a protein overexpressed on cervical tumor cells and vasculature, and deploys monomethyl auristatin E (MMAE) as its cytotoxic payload via a cleavable linker. On binding TF, TV internalises and releases MMAE to disrupt microtubule function and induce apoptosis.
“The tisotumab vedotin plus pembrolizumab combination is the most patent-dense regimen in this cervical cancer dataset — with parallel Genmab and MSD International GmbH filings spanning CA, AU, SG, MX, and CN jurisdictions.”
Multiple patent families from Genmab A/S and MSD International GmbH (Merck) cover TV in combination with anti-PD-1 antibodies — specifically using pembrolizumab’s CDR sequences — for cervical and breast cancer. The mechanistic rationale underpinning this combination is that MMAE-mediated immunogenic cell death enhances T-cell infiltration, which is then amplified by PD-1 blockade. A CN-jurisdiction filing from Merck’s Chinese entity explicitly identifies the TV + pembrolizumab combination for cervical cancer treatment, using defined CDR sequences for both antibody components.
The clinical translation signals embedded in these filings are notable. The AU-jurisdiction filing (2026 date) extends coverage in a manner consistent with ongoing clinical data generation. Multiple filings contain specific dosing schedules, administration sequences, and adverse event management language — including premedication protocols — which typically reflect clinical protocol design rather than early-stage research claims.
Track the full tisotumab vedotin patent landscape across all jurisdictions in real time.
Explore Patent Data in PatSnap Eureka →Tisotumab vedotin (TV) is an anti-Tissue Factor (TF) antibody-drug conjugate that links the anti-TF antibody tisotumab to MMAE via a cleavable linker. Patent filings from Genmab A/S and MSD International GmbH cover the TV plus pembrolizumab combination for cervical cancer across CA, AU, SG, MX, and CN jurisdictions.
PD-1/PD-L1 Inhibitors and Biomarker-Driven Patient Selection
PD-1 axis inhibition is the most frequently addressed therapeutic axis in the retrieved dataset, with six distinct patent families from Regeneron Pharmaceuticals, AstraZeneca, and Chinese biotechs describing anti-PD-1 or anti-PD-L1 therapies specifically for cervical cancer. What distinguishes the most advanced filings is not just the therapeutic claim, but the granularity of biomarker-based patient selection criteria.
Cemiplimab: The Broadest Jurisdictional Footprint
Regeneron Pharmaceuticals holds the highest volume of cervical cancer-specific patent filings in the dataset — five or more distinct jurisdictional filings for cemiplimab across US, WO, AU, IL, MX, and CN. Claims are directed to recurrent or metastatic cervical cancer with progression on chemotherapy, with patient selection based on PD-L1 expression thresholds ranging from ≥1% to ≥50% tumor proportion score. Critically, one Regeneron filing also references HPV E6 and E7 oncogene expression as biomarkers, directly connecting HPV tumor biology to immune checkpoint inhibitor eligibility.
Regeneron’s cemiplimab filings identify HPV E6 and E7 oncogene expression as patient stratification biomarkers for PD-1 inhibitor therapy in cervical cancer — the first signal in this dataset connecting HPV biology directly to checkpoint inhibitor eligibility criteria.
The multi-jurisdictional footprint covering the same treatment method (US, WO, AU, IL, MX, CN) suggests IP protection is contemporaneous with or follows clinical trial conduct. References to platinum-refractory patient populations — specifically patients previously treated with platinum, paclitaxel, and/or bevacizumab — align with second-line clinical trial eligibility criteria as defined by organisations such as ASCO.
Durvalumab and the Locally Advanced Setting
AstraZeneca’s cervical cancer filings represent a strategically distinct direction: moving checkpoint inhibition earlier in the disease course by combining anti-PD-L1 (durvalumab) or anti-PD-1 binding proteins with cisplatin-based chemoradiation therapy (CRT) for locally advanced cervical cancer (LACC). Two filings in WO and AU jurisdictions reference progression-free survival (PFS) extension and overall response rate (ORR) as endpoints — language consistent with clinical trial outcome reporting. The bispecific antibody MEDI5752 (targeting both PD-1 and CTLA-4) is referenced in one filing as an alternative therapeutic backbone.
Chinese biotech activity adds a further dimension: Guangzhou Yuheng Biological Technology Co., Ltd. describes an anti-PD-1 antibody for PD-L1-positive cervical cancer after platinum-based chemotherapy (CN, 2022), while Bio-Thera Solutions addresses anti-PD-1 combined with taxane/platinum ± bevacizumab (CN, 2025). These CN-jurisdiction filings reflect a domestic Chinese pipeline that mirrors the combination strategies pursued by Western originators. Patent databases maintained by the EPO confirm increasing Chinese-origin filings in oncology immunotherapy over the same period.
Regeneron Pharmaceuticals holds 5 or more distinct jurisdictional patent filings for cemiplimab in cervical cancer — across US, WO, AU, IL, MX, and CN — with patient selection criteria specifying PD-L1 expression thresholds of ≥1% to ≥50% and HPV E6/E7 oncogene status as biomarkers.
TIGIT, HER2, and the Next Wave of Combination Strategies
Beyond the established PD-1 and TF-ADC pillars, the retrieved dataset reveals a set of emerging secondary targets that signal the next phase of cervical cancer drug pipeline development. TIGIT, HER2, and ICOS each represent distinct mechanistic rationales for expanding beyond single-checkpoint inhibition.
TIGIT/PVR: A Dual-Biomarker Selection Model
F. Hoffmann-La Roche AG has filed patents across WO, AU, CA, and CN jurisdictions explicitly naming cervical cancer — including Stage IVB, metastatic/recurrent, and PD-L1-positive carcinoma — as a target indication for anti-TIGIT antagonist antibody tiragolumab combined with anti-PD-L1 atezolizumab. What distinguishes the Mereo BioPharma 5, Inc. filing (WO, 2023) is a biomarker selection framework that identifies PVR (CD155) positivity combined with PD-L1 positivity as a predictive signature for anti-TIGIT plus anti-PD-1 response in cervical cancer. This dual-biomarker model moves beyond PD-L1 alone as a patient stratification tool — a meaningful refinement given the heterogeneous PD-L1 expression observed in cervical tumors. As noted in research published by Nature, dual immune checkpoint blockade strategies are increasingly being evaluated in solid tumors with mixed checkpoint expression profiles.
HER2: A New Subgroup-Defined Axis
RemeGen Co., Ltd.’s 2025 WO filing introduces anti-HER2 ADCs — comprising an anti-HER2 antibody conjugated to a cytotoxic molecule — for treating HER2-expressing cervical cancer, both as monotherapy and in combination with anti-PD-1 antibodies. This signals the potential segmentation of the cervical cancer population by HER2 status, creating a subgroup-defined therapeutic axis that parallels developments in gastric and breast cancer. The filing lacks the clinical language specificity seen in the TV and cemiplimab families, suggesting an earlier translational stage. Drug developers should assess whether HER2 expression rates in cervical tumor cohorts justify further IP investment in this axis.
ICOS and CD137: Broadening the Co-Stimulatory Landscape
GlaxoSmithKline Intellectual Property Development Limited has filed for an ICOS binding protein combined with PD-1 inhibition (and optionally TIM-3) in cervical cancer alongside head and neck cancer, lung cancer, urothelial cancer, and melanoma. Eli Lilly and Company has filed a WO patent covering anti-CD137 antibodies for combination with anti-PD-1 antibodies across multiple tumor types. These filings are less cervical-cancer-specific but extend the co-stimulatory pathway landscape beyond TIGIT.
Monitor emerging TIGIT, HER2, and ICOS combination strategies across the full cervical cancer patent landscape.
Analyse with PatSnap Eureka →While HPV oncoproteins E6 and E7 appear in Regeneron’s cemiplimab filings as patient selection biomarkers, no direct anti-HPV therapeutic — such as a therapeutic vaccine or E6/E7 inhibitor — was identified in the retrieved patent dataset. HPV-targeted therapeutics appear to remain an academic research frontier rather than an active commercial patent space within this dataset.
Assignee Landscape and Strategic IP Positioning
Innovation activity in this dataset is predominantly patent-driven, with no standalone academic papers retrieved. The assignee landscape reveals clear differentiation in IP strategy: Regeneron leads on breadth of jurisdictional coverage for a single agent, while Genmab and Merck lead on combination-specific IP construction across multiple geographies.
Regeneron Pharmaceuticals holds the highest volume of cervical cancer-specific patent filings in the dataset, with 5+ distinct jurisdictional filings for cemiplimab. The breadth of geographic coverage — US, WO, AU, IL, MX, CN — and the specificity of patient selection criteria (PD-L1 ≥1–50%, HPV oncogene status) suggest a mature IP strategy contemporaneous with or following clinical trial conduct.
Genmab A/S and MSD International GmbH (Merck) have constructed parallel and joint filings in CA, AU, SG, MX, and CN covering the TV + pembrolizumab combination. The presence of both originator (Genmab) and commercial partner (Merck) filings signals active co-development IP construction. The 2026 AU-jurisdiction filing from Genmab extending coverage is consistent with ongoing clinical data generation from the combination regimen.
AstraZeneca AB occupies a distinct strategic niche: its cervical cancer filings (WO, 2024; AU, 2026; CN, 2026) target the locally advanced setting — combining PD-L1/PD-1 inhibition with chemoradiation therapy — rather than the recurrent/metastatic space dominated by Regeneron and Merck. This represents a potentially differentiated IP position in an under-claimed subpopulation. IP strategy resources from WIPO highlight the growing importance of indication-specific patent stratification in oncology portfolios.
F. Hoffmann-La Roche AG holds a broad anti-TIGIT portfolio listing cervical cancer among multiple tumor types, filed across WO, AU, CA, and CN. Chinese biotechs — Guangzhou Yuheng Biological Technology Co., Ltd. and Bio-Thera Solutions — contribute CN-jurisdiction filings targeting PD-1 monotherapy and PD-1 + chemotherapy combinations, reflecting active domestic Chinese pipeline development. RemeGen Co., Ltd. and Mereo BioPharma 5, Inc. represent emerging, niche positions in HER2 ADC and TIGIT biomarker selection respectively.
“The locally advanced cervical cancer subpopulation is a distinct and under-claimed IP space — AstraZeneca’s PD-L1/PD-1 plus chemoradiation filings may represent a differentiated positioning versus the recurrent/metastatic setting dominated by Regeneron and Merck.”
For IP strategists and drug developers, the key strategic implication is that the recurrent/metastatic cervical cancer space is becoming increasingly crowded around PD-1 axis inhibition and TF-ADC combinations, while LACC, HER2-positive subgroups, and TIGIT/PVR-defined populations remain comparatively open. Monitoring filing activity from PatSnap’s IP management tools across these emerging axes is essential for competitive intelligence. The PatSnap R&D intelligence platform provides real-time patent landscaping across all therapeutic modalities discussed in this analysis.
AstraZeneca AB’s cervical cancer patent filings (WO 2024, AU 2026, CN 2026) target the locally advanced cervical cancer (LACC) setting — combining anti-PD-L1 durvalumab or anti-PD-1 binding proteins with cisplatin-based chemoradiation therapy — representing a distinct IP position from the recurrent/metastatic space dominated by Regeneron and Merck.